SUMMARY Transdermal scopolamine is an antimuscarinic preparation approved for use in the United States for prevention of motion sickness. A recent study using this drug (0-5 mg/patch) suggested that enough scopolamine was absorbed through the skin to reduce basal gastric acid secretion in patients with duodenal ulcer. We have compared the effect of transdermal scopolamine and oral cimetidine (400 mg twice daily) in seven men with chronic duodenal ulcer, both alone and in combination, on acid secretion throughout an entire 24 hour period in a placebo-controlled, randomised, double blinded cross over study. The effect of these drugs on basal, interprandial, and nocturnal gastric juice volume and hydrogen ion concentration also was measured. Transdermal scopolamine had no significant effect on mean 24 hour acid secretion (placebo, 409-4 mmol/day; scopolamine, 364.0 mmol/day) nor did it have a significant effect on gastric juice volume or hydrogen ion concentration. The combination of transdermal scopolamine plus cimetidine was not more effective than cimetidine alone in reducing total 24 hour acid secretion (mean, 231*8 versus 235-3 mmol/day) nor in reducing gastric juice volume or hydrogen ion concentration.
Transderm-Scop (TDS, Ciba-Geigy Corp, Summit, NJ.) is a sustained release formulation of the antimuscarinic drug, scopolamine (1-hyoscine), de- signed to allow continuous absorption of this belladonna alkaloid from a patch applied to the skin. After delivering a local, skin saturating loading dose, the transdermal system delivers about 0-5 mg of scopolamine at a constant rate over three days (at a rate of about 7 .tg/h or 01 ,ug/kg/h). Transderm scopolamine is approved by the Food and Drug Administration in the United States for prevention of nausea and vomiting associated with motion sickness. Two recent studies' 2 have suggested that the amount of scopolamine absorbed through the skin is sufficient to inhibit basal and nocturnal gastric acid secretion in patients with duodenal ulcer, suggesting that this product could be useful and convenient as a gastric antisecretory agent.
We evaluated in a placebo controlled, randomised study the effect of transderm scopolamine on acid secretion in duodenal ulcer patients studied over an entire 24 hour period, during which breakfast, lunch, and dinner were given. The effect of transdermal scopolamine on 24 hour acid secretion was compared with the effect of cimetidine taken in a dose of 400 mg twice daily, a dose which accelerates healing of duodenal ulcers.3 4 Because some antimuscarinic drugs enhance the inhibitory effect of histamine H2-receptor antagonists on gastric acid secretion,5 6another purpose of these studies was to determine whether the combination of transdermal scopolamine and oral cimetidine was more effective than cimetidine alone in reducing 24 hour gastric acid secretion in duodenal ulcer patients. Basal, interprandial and nocturnal gastric juice volume and hydrogen ion concentration were also compared. juice sample pH was converted to hydrogen ion concentration by the method of Moore and Scarlata.9 Acid secretion during the basal, interprandial and nocturnal periods (see below) was calculated by multiplying the volume times hydrogen ion concentration of each gastric juice sample.
From 9 am to 11 am, acid secretion in response to the liquidised breakfast meal was measured by in vivo intragastric titration to pH 5-0 with 0 3 N sodium bicarbonate. U) At 11 am, the stomach contents were emptied and gastric aspiration resumed until 2 pm. Acid secretion in response to lunch was measured by in vivo titration from 2 pm until 4 pm. The stomach was emptied again at 4 pm and aspiration resumed until 7 pm. Acid secretion in response to dinner was measured by titration from 7 pm until 9 pm. Then, after the stomach was emptied, nocturnal acid secretion was measured by aspiration from 9 pm until 8 am the next morning. To prevent volume depletion as a result of prolonged aspiration of gastric juice, isotonic saline was infused intravenously at a rate of 75 ml/h (from 8 am to 9 pm) or 100 ml/h (from 9 Cimetidine and the combination of cimetidine plus transdermal scopolamine reduced hydrogen ion concentration significantly during both interprandial periods and during the night. The drug combination was not more effective than cimetidine alone in decreasing hydrogen ion concentration.
Discussion
By combining the techniques of gastric aspiration8 and in vivo intragastric titration,tt1 we have developed a method for measuring acid secretion throughout a 24 hour period, including acid secretion in response to three meals, the periods after the meals and during the night. We have previously applied this technique for comparison of 24 hour acid secretion in normal subjects and duodenal ulcer patients and to evaluate the effect of cimetidine and parietal cell vagotomy on 24 hour acid secretion.7 Data from previous studiest suggest that antimuscarinic drugs reduce basal and nocturnal acid secretion by about 40-60%. Because two recent reports indicated that transdermal scopolamine reduced basal acid secretion by 65%t and nocturnal acid secretion by 75% in duodenal ulcer patients2 and because the drug is commercially available for the prevention of motion sickness, we felt it was important to study and report the effect of transdermal scopolamine on acid secretion throughout an entire 24 hour period in duodenal ulcer patients. While transdermal scopolamine reduced 24 hour acid secretion slightly in six out of seven patients, we could not confirm a significant inhibitory effect of transdermal scopolamine on basal, interprandial or nocturnal acid secretion nor did we find a significant effect of the compound on gastric juice volume or hydrogen ion concentration (Tables 2-4) . Furthermore, transdermal scopolamine reduced total 24 hour acid secretion by only 9±5% (range, -18 to 23%, p>0 (5) . Transdermal scopolamine also did not enhance the inhibitory effect of cimetidine on acid secretion (Table 1 and Figure) as has been reported with other antimuscarinic drugs.' 6 We are uncertain why our data disagree with other recent reports.' 2 Possibilities include differences in patient selection or in study design. For example, placebo and transdermal scopolamine were administered in random order in our study, whereas the placebo (control) experiment had always preceded transdermal scopolamine in one of the previous studies.2 This 
